SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation

News Medical

Center

Mixed Factuality

Other: Ian Birkby

SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation

SOLASCURE Ltd (SolasCure), a biotechnology company developing a hydrogel containing a recombinant enzyme derived from maggots which aims to accelerate wound debridement, has announced the completion of its GBP 10.9m (c. USD 13.3m) Series B investment round. The funding round was led by Seneca Partners and also included industry veterans, institutional venture and strategic investors, including BRAIN Biotech AG, EVA Pharma, Jonathan Milner, and W…